British pharmaceutical giant GSK agrees to buy Canadian Bellus Health

GSK has agreed to purchase Bellus Health for £1.6 billion ($2 billion) at $14.75 per share.

In the statement, it was stated that the Canadian pharmaceutical company specializes in the treatment of respiratory problems and cough, and that the purchase agreement is expected to make a great contribution to GSK in these areas.

Emphasizing that the drug named “Camlipixant”, which was developed by Bellus Health and seems to be good for cough, is already in the final phase of the clinical testing process, it was also reminded that 6 million people in the USA and the European Union suffer from chronic cough.